Genetic Disorders | CHOP Research Institute
 

Genetic Disorders

Published on
Nov 27, 2024
A study funded by the National Heart, Lung, and Blood Institute aims to improve blood transfusion outcomes.

This extension study will determine the long-term safety and effectiveness of mRNA-3705, a treatment for Methylmalonic acidemia (MMA), in patients who previously enrolled in and completed a prior mRNA-3705 study.

This is a Phase ½ study testing an experimental gene therapy developed by Atsena Therapeutics for X-Linked Retinoschisis (XLRS).

Published on
Sep 19, 2024
CHOP researchers developed a factor VIII variant that led to safe and long-lasting therapeutic results in preclinical models.
Published on
Jun 13, 2024
At CHOP’s Leukodystrophy Center, researchers are aiming to reduce the length of the prolonged diagnostic odyssey that many patients with MLD encounter.
Published on
May 29, 2024
Decades ago, Katherine A. High, MD, and colleagues began an unprecedented journey to develop a new kind of treatment for hemophilia B.
Published on
May 18, 2023
Scientists from Children’s Hospital of Philadelphia attend the American Society of Cell & Gene Therapy Annual Meeting to share their expertise through posters, panel discussions, and workshops.

Our team at the Congenital Hyperinsulinism Center at CHOP is working on a research study to determine whether an experimental gene therapy product, DTX401, is safe and effective in people with glycogen storage disease type Ia (GSDIa)

Published on
Oct 21, 2021
Findings support lysosomal acidification strategies for pediatric neurodegenerative disorders with impaired mitochondrial quality control.

We are doing this study to see if the patterns of abnormalities in controlling insulin in children and adults with hyperinsulinism are related to any underlying genetic cause and to identify possible new genetic causes.